Newsletter February 2022 – A big start to a big year for Cline
The Cline Scientific team is excited to bring you the first newsletter of 2022 and share the current projects and upcoming activities. This quarter marks a significant milestone for the StemCART project, with the first stage of ex-vivo testing now underway. StemCART Cline’s cell-based therapy in development, StemCART, aims to repair cartilage damage through a unique combination of allogeneic induced pluripotent stem cell (iPSC)-derived chondrocytes and a support matrix. The creation of these reparative cells is made possible by Cline’s proprietary nanotechnology that enables the